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Multiple sclerosis is the most common chronic autoimmune disease of the central nervous system which
preferentially affects females at childbearing age. For this reason, patients and treating physicians were frequently
confronted with questions concerning family planning, pregnancy and birth. Preventive and personalized treatment
approaches are considered, because topics as heredity, risk of congenital malformations, influence of pregnancy on
MS and aspects of drug therapy during the period of conception, pregnancy, puerperium and lactation have to be
discussed. Here, we provide an overview about the current state of knowledge regarding these issues.Review
Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease
of the central nervous system which, at the beginning,
typically arises with relapsing episodes of neurological
deficiencies. Subsequently, symptoms may persist, and in
approximately 65% of the patients, a conversion into a
secondary progressive (SP) course with a continuous de-
terioration of disability occurs. Patients (15-20% of the
patients suffer from a primary progressive (PP) MS with
a steady worsening of symptoms from onset [1]).
Until now, pathomechanisms of MS are not suffi-
ciently understood. Inflammatory demyelinating as well
as neuroaxonal degenerative processes are involved in
pathogenesis and result in cerebral and spinal tissue
damage [1].
Treatment of acute exacerbation includes usually the
application of intravenous methylprednisolone for 3 to
5 days [2,3]. To reduce frequency and severity of
relapses as well as the progression of disease in general,
an immunomodulatory therapy with interferon beta
(IFN-β) or glatiramer acetate (GA) is necessary [4,5]. In* Correspondence: nadja.borisow@charite.de
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reproduction in any medium, provided the orpatients with high disease activity or insufficient effect of
IFN-β or GA, the monoclonal antibody natalizumab or
the sphingosine receptor modulator, fingolimod, is avail-
able [6,7]. Another agent, which is approved for second-
line-therapy, is mitoxantrone [8]. Of particular import-
ance to reduce relapses and disease progression is an
early initiation as well as a long-lasting and continuous
administration of these therapies [9,10].
In Europe, MS prevalence rates range between 10 and
187 per 100,000 with a higher rate in northern countries
[11]. In Germany, approximately 120,000 people suffer
from MS [12]. Patients typically experience first symp-
toms between the 3rd and 5th decade of life, and thus,
MS mainly affects patients in childbearing age. It shows
a female predominance of 2 to 3:1 [11-13]. Conse-
quently, a high need for counseling exists on topics as
family planning, pregnancy and child birth. Seeing that
even healthy couples have many concerns related to
pregnancy, such concerns particularly apply to patients
with chronic and progressive diseases such as MS.
As especially the field of family planning, pregnancy
and child birth benefits from a shift from delayed inter-
ventional to preventive and personalized medicine, in
this article, an update about the current state of know-
ledge regarding the process of decision making, heredity
and fertility, as well as course and outcome ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cuss the influence of pregnancy and childbirth on the
disease, aspects of breastfeeding and concomitant medi-
cation, and finally encourage MS patients not generally
to abstain from child birth due to their disease.
Influence of MS on family planning and personalized
approach in decision making
In patients with MS, a lot of different aspects and con-
cerns influence the decision whether to bear a child or
not [14]. In the past, especially during the first half of
20th century, female patients were often discouraged
from becoming mother as pregnancy was considered to
be a risk in MS [15]. Today, first and foremost, there is
the fear about the future state of health and the asso-
ciated ability of taking care for the baby. The unpredict-
able course of the disease and the known increase of
relapses postpartum [16] lead to further uncertainty
regarding getting pregnant. Disabilities, e.g., pareses or
impaired coordination may result in a higher risk of in-
jury for the infant. Further anxiety exists regarding gen-
etic predisposition and passing the disease on to their
offspring. Moreover, the necessity to pause virtually all
established disease-modifying therapies during the
period of conception, pregnancy and breastfeeding raises
the possibility of disease progression. Frequently,
patients feel pressured by family members or health pro-
fessionals either to abstain from pregnancy due to vari-
ous problems MS is related with or to bear children as
soon as possible in an early stage of disease. The fear of
asking others for help and finally financial restrictions
are other aspects patients with MS are confronted with
while planning a family. In a widely larger extent than in
healthy women in patients with MS, other persons be-
sides the partner are involved in the process of decision
making regarding getting pregnant [17]. The patients try
to get into conversation especially with other family
members, foremost their mothers, as they are aware they
could rely on them in case of a relapse. Depending on
the relationship and the sense of togetherness within the
family, these talks may be encouraging as well as dissua-
sive. Also, treating physicians were frequently consulted
to achieve an additional advice from the medical point
of view.
Several studies were published regarding the correl-
ation between MS and family planning, especially child
birth, to some extent with contradictory results. A
French study revealed a relationship between age at
onset of the MS and the number of children who are fi-
nally born [18]. A clear association between an early dis-
ease onset (<25 years) and a lower number of children
could be shown, even though patients with an onset
>25 years get less children than the general French
population. Interestingly, there is no difference betweenmen and women [18]. A Swedish study shows that, even
at onset of the disease, the proportion of childless
women is higher in female MS patients compared to
healthy women of same age [19]. The reasons are not
clear; maybe a reduced fertility even before onset of the
disease has to be discussed.
MS inheritance risk as factor influencing individual
decision making in family planning
From the perspective of preventive medicine, knowledge
about inheritance risk is essential for making informed
decision about planning or continuing a pregnancy.
Broad consensus exists that environmental as well as
genetic factors are involved in the etiology of MS. The
lifetime risk for MS in the general population of north-
ern Europe is 0.2% to 0.5% with higher rates in northern
countries. As epidemiologic studies show, risk of MS
increases with raising degree of kinship to a MS patient.
Highest risks are described in monozygotic twins, fol-
lowed by siblings, parents and children of MS patients
[20-25]. Second and third degree relatives have a lower
risk, although it is still higher than in general population.
Among stepsiblings and adopted relatives, no elevated
MS risk was found [26,27]. Table 1 gives an overview
about studies examining risk of MS in children of male
and female MS patients. If not mentioned by the
authors, relative risks were calculated by using age-
adjusted risks and lifetime risk in general population.
To sum up, children of MS patients are at 6- to 12-
fold risk of developing MS with age-adjusted risks ran-
ging between 1.5% and 7%. One study even describes a
50-fold risk in daughters of MS patients [24], but all in
all, the likelihood of not getting the disease in children
of MS patients is approximately 97%.
Oral contraception - a measure of prevention in MS?
As the intake of oral contraception might play a prevent-
ive role in MS, a couple of studies examined the influ-
ence of oral contraception on risk, onset and course of
MS. In summary, there is no positive proof of an effect
of oral contraceptives on the lifetime risk for develop-
ment of MS [28-30]. In patients with PP MS, the use of
oral contraception showed both a higher risk to reach an
Expanded Disability Status Scale (EDSS) of 6 and a
shorter duration between onset of MS and EDSS 6 [31].
In women with relapsing onset of the disease, no influ-
ence of oral contraception on disease progression was
found. In contrast to that, another study suggests a pro-
tective effect of contraceptives as it shows a correlation
between use of oral contraception and a higher age at
onset, even though in this study, no differentiation be-
tween relapsing and progressive MS was conducted [32].
Another survey as well postulated a possible delay of MS
onset in patients using oral contraceptives [33]. Finally,
Table 1 Overview of studies on MS risk in children of MS patients

















2005 Denmark 8205 Men, 0.3;
women, 0.5
- Daughter 7.5 - Daughter 4.5
Son 7.5 Son 9.5
Total 7.5 Total 6.3
Prokopenko
et al. [23]
2003 Italy (Sardinia) 313 0.157 - - Total 3.19 Total 20.3
Carton et al. [22] 1997 Belgium 674 0.175 Total 1.51 Total 8.6 Total 1.87 Total 10.7
Robertson
et al. [21]
1996 UK 674 0.3 (men, 0.13;
women, 0.66)
Daughter 7.12 Daughter 10.8 Daughter 1.74 Daughter 2.6
Son 2.54 Son 19.5 Son 0.0 Son 0.0
Total 4.91 Total 16.4 Total 0.81 Total 2.7
Sadovnick
and Baird [24]
1988 Canada 815 0.1 Daughter 5.13 Daughter 51.3 Daughter 4.96 Daughter 49.6
Son 0.0 Son 0.0 Son 0.0 Son 0.0
Total 2.47 Total 24.7 Total 2.58 Total 25.8
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MS, it seems to be important to differentiate between in-
flammatory and degenerative processes in the disease
course.
Fertility in MS patients
To explain the higher proportion of childlessness among
MS patients, various factors have to be discussed. As
mentioned above [19], among others, a reduction of fer-
tility even in the preclinical phase of disease has to be
considered. Fertility may be influenced by numerous
parameters including sexual dysfunctions and hormonal
alternations.
One study in 73 German female MS patients revealed
an average period of 4 months to get pregnant and con-
cluded no reduction in fertility in women with MS [34].
However, only females who were already mothers were
included in this study which implies that women with
limited fertility, leading to childlessness, were not taken
into account at all. Thus, this study potentially underes-
timates the prevalence of reduced fertility in female MS
patients. In fact, another survey found a significantly
higher need for artificial insemination in female patients
with MS compared to the general population obtained
from Finnish Medical Birth Register [35].
Even in MS patients with mild neurologic deficits, up
to 73% complain about sexual dysfunctions [36,37]. In
female patients, reduced libido, decreased vaginal sensa-
tion and lubrication as well as difficulties in reaching an
orgasm were described [38]. Male patients complain
about erective dysfunction, impaired ejaculation, and just
as female patients, about reduction of libido [39]. Des-
pite same marital status, a significantly lower frequency
of sexual intercourse in patients with MS compared to
both healthy controls and patients with rheumatic dis-
eases, especially with rheumatoid arthritis, can be
detected [37]. In addition to sexual dysfunctions causedby MS, other disease-related physical impairments may
interfere with sexual activity. Above all, fatigue is a fre-
quently mentioned symptom; furthermore, muscle weak-
ness, constraints of coordination, pain, spasticity and
impaired sensation may have negative effects on sexual-
ity. In addition, medication used to treat attendant
symptoms as depression, anxiety, or urinary urgency
may account for sexual dysfunctions. That is why a per-
sonalized approach to concomitant medication is
required, particularly in MS patients at childbearing age.
Several hormonal alterations which may interfere with
fertility have been described in patients with MS. Signifi-
cantly higher levels of FSH, LH, prolactin and testoster-
one were detectable in female patients [40]. In men,
lower levels of testosterone, LH and FSH, as well as
pathologic GnRH and hCG tests, were observed. Above
all, pathologic spermiograms with a reduced number
and motility of semen were described [41].
Besides these aspects, psychological factors may not be
underestimated. Shame because of physical disabilities,
bladder or bowel dysfunctions, inserted catheters, or the
fear of disapproval by the partner may lead to avoidance
of sexual contacts. Whether and to what degree these
factors in detail lead to a higher rate of undesired child-
lessness in MS-patients is not clear. To our clinical ex-
perience, fertility is not reduced in a significant way in
MS patients; besides this, most women become pregnant
in the earlier phase of the disease without profound
disability.
Influence of motherhood on MS
Studies analyzing the influence of pregnancy and child
birth on incidence, onset, course, or severity of MS
under the aspect of a possibly preventive effect have to
be interpreted with caution as cause and effect are diffi-
cult to differentiate. A Danish study investigated the re-
lationship between the number of born children and the
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versely associated with the number of born children and
with the age at birth of the first child. Furthermore, the
MS risk was reported to increase with time since birth
of the most recent child. Moreover, the number of chil-
dren born before diagnosis of MS is associated with a
higher age at onset of the disease [32]. In addition, the
pregnancy with or birth of at least two children leads to
a lower likelihood to reach an EDSS score of 6, respect-
ively to the extension of the period until EDSS 6 is
achieved, at least in patients with relapsing-remitting
(RR) MS [31]. If the first child is born after onset of MS,
the risk of conversion from RR MS to SP MS is lower
compared to women whose children were born before
onset of the disease [19]. Furthermore, pregnancy after
onset of MS is associated with a longer duration until
wheelchair dependence develops compared to patients
who were never pregnant or born children only before
onset of the disease [43]. To sum up, motherhood does
not seem to have negative effects on risk or course of
MS, although the interpretations of all these studies
need to factor a possible bias as women with severe
course of the disease may tend to prevent pregnancies,
and rather patients with benign forms or late onset of
the disease decide to become pregnant.
Influence of pregnancy on MS course
The level of knowledge about the effect of pregnancy on
MS and vice versa is low in female patients [44], al-
though numerous studies investigated the influence of
pregnancy on MS. A prospective study examining the
course of pregnancy in about 250 patients, the PRIMS
study, revealed a reduction of the relapse rate during
pregnancy, especially during the third trimester [16].
Over a period of 3 months after delivery, relapse rate
increased to a level higher than before pregnancy fol-
lowed by a decrease to pre-pregnancy rate during the
next 6 to 9 months. These results confirmed the findings
of previous partly retrospective, partly quite small stud-
ies [45-47] and were verified by following surveys
[48,49]. Relapses in the year before and during preg-
nancy are supposed to be a risk factor as they lead to a
1.7- to 1.8-fold increase of postpartum relapses [50], al-
though these results could not be confirmed by another
survey [51].
Immunologic changes during pregnancy aiming at
protecting the fetus from maternal immune defense are
supposed to lead to the observed reduction of disease
activity during proceeding pregnancy. An increase of
CD4+/CD8+ ratio and a decrease of CD16+ natural killer
(NK) cells during pregnancy, followed by a decline in
CD4+/CD8+ ratio and a rise in CD16+ NK cells after de-
livery may represent a correlate of maternal immune
suppression which may explain some of the detectedchanges in disease activity during and directly following
pregnancy [52].
Assisted reproduction technique in MS patients
As approximately 10% to 15% of all couples in general
population remain undesirably childless, artificial
fertilization may also be necessary in patients with MS.
Until now, three studies investigated the effect of
assisted reproduction technique (ART) on the course of
the disease. Laplaud et al. found an increased relapse
rate in patients treated with LHRH agonists, but not in
females after treatment with LHRH antagonists [53].
Two further surveys confirmed the observed elevation in
relapse rate during ART, although in these studies, the
increased relapse rate was not dependent on the type of
hormonal treatment [54,55]. Generally, we do not rec-
ommend to refrain from ART but inform about the
increased risk and counsel to stay on MS treatment
while undergoing ART.
Multidisciplinary approaches on course and outcome of
pregnancy in MS patients
Additional causes of concern in expectant mothers with
MS are possible complications during pregnancy or de-
livery. A study comparing 432 births in 321 MS patients
with healthy controls showed no differences in birth
weight, mean gestational age, labor duration or 5-mine
APGAR score [56]. Some surveys revealed a significant
lower birth weight in newborns of MS patients, although
the difference was low, ranging between 108 and 123 g
[57,58]. A meta-analysis evaluating the results of 22
studies published between 1983 and 2009 found no ele-
vated risk of low birth weight by analyzing the propor-
tion of newborns with a birth weight <2500 g.
Furthermore, no increased rate of abortions, prematur-
ity, malformations or neonatal deaths in children of fe-
male MS patients was detected [59]. One study in nearly
200 pregnant women with MS provided evidence for a
significantly higher rate of maternal anemia which is,
due to a chronic intrauterine hypoxia, supposed to be
the reason for a higher rate of meconium aspiration in
infants of MS patients [60]. Despite these complications,
no differences in duration and way of delivery, APGAR
score directly after birth or necessity of assisted ventila-
tion were detectable. The frequency of other pregnancy-
related complications, such as gestational diabetes melli-
tus or preeclampsia, was comparable to healthy controls.
In some surveys, operative deliveries with use of for-
ceps or vacuum extraction were more frequent in MS
patients [35,57,60], which is attributed to a higher risk of
exhaustion and slow progression of delivery in these
patients. The rate of deliveries by cesarean section
among MS patients shows a wide range between 10%
and 40% [59]. In general, proportion of cesarean section
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tries, influenced by social, religious and cultural factors.
Concern regarding present or potential MS-related
symptoms during delivery, such as spasticity, neuromus-
cular perineal weakness or exhaustion, is a factor that
may influence the decision of patients and physicians in
favor of cesarean section. Delivery mode and use of epi-
dural analgesia do not influence postpartum relapse rate
[16]. Taken together, the fact of suffering from MS is no
reason to choose cesarean section instead of vaginal de-
livery, but obstetrical rationale should be the basis for
decision making. Multidisciplinary approaches are
required to guarantee an optimized treatment.
It has to be taken into account that some cohorts,
investigated for pregnancy outcomes, included, first and
foremost, women with a low EDSS score [35,56]. Data
on rate of pregnancy and delivery complications in
women with higher disability are rare, most likely be-
cause they are difficult to recruit, as women with distinct
deficits rather avoid pregnancies. Furthermore, a higher
rate of obesity in women with MS, e.g., due to less activ-
ity caused by physical disability, is discussed to possibly
elevate the risk of complications during pregnancy and
delivery.
Breastfeeding - a countermeasure against postpartum
relapses?
Several studies examined the influence of breastfeeding
on the course of the disease, especially on the occur-
rence and frequency of postpartum relapses, with finally
inconsistent results. Some studies postulated a protective
effect of exclusive breastfeeding [61-63] with a signifi-
cantly higher risk for postpartum relapses in women that
abstain from nursing. One study described a correlation
between a decrease in interferon gamma producing CD4
+ cells and postpartum relapses, which may be prevented
by exclusive breastfeeding due to lactational amenorrhea
[64]. On the other hand, the PRIMS study and a number
of further investigations found no relationship between
breastfeeding and postpartum relapses [16,65,66]. The
major difficulty in all these studies is to correctly inter-
pret the causality, as many women stop breastfeeding
due to a relapse and treatment with corticosteroids,
which may be suggestive of a higher rate of relapses in
women that do not nurse at all or only for a short period
of time. Except the fact that there is no proof of negative
effects of nursing on the course of MS, at the moment, a
clear recommendation regarding breastfeeding as a
measure for prevention of postpartum relapses cannot
be made. The appreciation between early resumption
or the beginning of immunomodulatory therapy after
delivery on one hand and the beneficial effects of
breast milk on the other hand raises a lot of uncertain-
ties. As long as no advantage of breastfeeding on MScourse is proven, treating physicians together with the
patient have to weigh up the benefit and the risk for
relapses by taking into consideration the frequency
and severity of disease course before pregnancy to
realize an individually tailored and optimized medical
care.
Personalized medication during pregnancy - a challenge
in MS treatment
The topic which certainly requires most counseling in
patients with MS who wish to conceive is the field of con-
comitant medication. This contains disease-modifying
therapy, immunosuppressive agents and steroids, as well
as medication required to treat MS-related symptoms.
As no reliable data concerning safety during pregnancy
exist, it is generally recommended to discontinue disease-
modifying therapy as IFN-β or GA either at the beginning
of unprotected sexual intercourse or at the latest after
pregnancy becomes known. Although data regarding drug
exposure in human gravidity mainly result from un-
planned pregnancies and are usually restricted to the first
weeks of pregnancy, they are of particular importance as
they help to make personalized treatment decisions in
pregnant MS patients.
One study showed a significantly increased rate of
spontaneous abortion and a reduction of birth weight
after exposure to IFN-β [67]. Reduced birth weight could
be confirmed in some surveys [68,69], whereas others
found no reduction in birth weight or increased rate of
spontaneous abortion, still birth and congenital abnor-
malities [70-76]. A small survey, including ten patients
who continued therapy with IFN-β or GA during whole
pregnancy and postpartum, revealed no increased rate of
spontaneous abortion but lower birth weight and earlier
delivery after GA exposure [69]. Table 2 provides an
overview about the results of different studies on birth
outcome after exposure to IFN-β and/or GA. To sum
up, IFN-β and GA seem to be considerably safe during
pregnancy, so an induced abortion after exposure is
not mandatory. Regarding the safety of disease-modifying
therapy in male MS patients, one only partly prospective
study exists which did not show reduced birth weight
or length in comparison to babies of healthy women
[77].
Regarding the application of natalizumab during preg-
nancy, approximately 40 patients are reported in the lit-
erature, one case with accidental exposure until the
third trimester [78-80]. No elevated risks for spontan-
eous abortion, reduction of birth weight or lengths espe-
cially congenital malformation were found; however; due
to the sparse data it is not possible to rule out rare
complications.
As animal studies in fingolimod showed increased
rates of miscarriage and vascular malformations, its use
Table 2 Overview of studies on birth outcome after exposure to IFN-β or GA





Boskovic et al., 2005 [67] 23 Increased rate of spontaneous abortion (39%); decreased birth weight,
two major birth defects (Down syndrome, X-chromosome abnormality)
Sandberg-Wollheim et al., 2005 [73] 41 Normal spontaneous abortion rate, one birth defect (hydrocephalus)
Patti et al., 2008 [72] 14 Normal spontaneous abortion rate and birth weight; shorter gestational
period (37.8 weeks), no malformations
Hellwig et al., 2009 [71] 17 Normal miscarriage rate (2/17) and birth weight
Weber-Schoendorfer and Schaefer,
2009 [75]
69 31 Normal spontaneous abortion rate and birth weight, no preterm delivery;
two major birth defects (club feet, AV canal) under GA
Amato et al., 2010 [68] 88 Normal spontaneous abortion rate; lower birth weight and length;
no major birth defects
Salminen et al., 2010 [76] 13 In 9/13 exposure during whole pregnancy, normal spontaneous abortion
rate and birth weight, no birth defects
Fragoso et al., 2010 [74] 11 Exposure >7 months during pregnancy; normal spontaneous abortion
rate, birth weight and length
Sandberg-Wollheim et al., 2011 [70] 425 Normal spontaneous abortion rate, three major birth defects (VACTERL
syndrome, tetralogy of Fallot, solitary kidney)
Hellwig et al., 2011 [69] 7 3 Exposure during whole pregnancy; lower birth weight and earlier delivery
(GA); one malformation in IFN (valvular stenosis of pulmonary artery), one
in GA (penile hypospadia)
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ence in human pregnancy is missing.
Glucocorticoids are not considered to be safe during
the first 3 months of pregnancy, as an increased risk of
oral clefts cannot be excluded [81]. Furthermore, higher
rates of miscarriage and preterm births, as well as lower
birth weight, have been described [82]. In cases of severe
relapses glucocorticosteroids can be taken into account
individually. Beyond the first trimester, the use of gluco-
corticoids does not seem to be harmful to the baby [83].
In MS, chemotherapeutic agents are used as second- or
third-line therapy in highly active relapsing-remitting MS
or in progressive courses, but due to a high rate of side
effects, their use is limited. They are, in general, not recom-
mended during pregnancy, partly because of known terato-
genicity, partly due to missing data regarding possible
effects on and risks for embryo- or fetogenesis in human.
Methotrexate, as well as other chemotherapeutics, is con-
traindicated during pregnancy, as it leads to spontaneous
abortions and congenital malformations [84]. According to
manufacturers' information, cyclophosphamide is muta-
genic; in the case of an exposure during first trimester of
pregnancy, counseling regarding induced abortion should
be provided. The FDA classifies cyclophosphamide within
category D, which means that fetal risks are known, but in
individual cases, the potential benefit may outbalance the
risk. Two surveys report the neonatal outcome after mitox-
antrone exposure during pregnancy in MS patients; one of
them describes growth restriction without evidence of con-
genital malformation [85], and in another case, a child withPierre Robin sequence was born [86]. Mitoxantrone is
also classified within category D by FDA. In azathioprine,
until now, no teratogenic effect was reported in humans;
nevertheless, it should only be used after strict risk-benefit
analysis because, in some newborns, leuko- and/or throm-
bopenia were described.
Intravenous immunoglobulin (IVIG) is supposed to be
safe during pregnancy as no negative effects on gravidity
or fetal development have been reported. A retrospective
study found a significant reduction of relapse rate by
IVIG administration during pregnancy and postpartum
without any serious adverse effects [87]. However, IVIGs
are not approved for MS treatment in general, and not
much information about the efficacy for acute relapses is
available.
Table 3 summarizes FDA pregnancy classification of
different immunomodulatory and immunosuppressive
medication used in MS therapy.
Medication to treat MS-associated symptoms, e.g.,
oxybutynin in neurogenic bladder dysfunction, spasmoly-
tics as baclofen and tizanidine, or antidepressants such as
amitriptyline, citalopram or mirtazapine should only be
used after careful consideration between risks for the
unborn and gain for the mother. A detailed discussion on
supportive treatment options in the context of pregnancy
is, however, beyond the scope of this article.
Prevention of postpartum relapses
Especially the first months after delivery pose a challenge
for the newly minted parents and are particularly
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child. Unfortunately, just in the first 3 months after child
birth, the relapse rate in MS patients markedly increases.
Thus, finding an effective prevention for postpartum
relapses is a matter of particular importance. Based on
the hypothesis of a progestin-mediated immunological
shift from Th1 to Th2 response, which is considered an
important cause of reduced relapse rate during preg-
nancy, the POPART'MUS study examines the potential
of progestin and estradiol in preventing postpartum
relapses [88]. It is a prospective, placebo-controlled and
double-blinded study that aims to recruit 300 patients
and is still ongoing.
Intravenous corticosteroids are supposed to reduce
postpartum relapse rate [89]; however; until now; pro-
spective randomized double-blinded studies are missing.
A postpartum therapy with intravenous immunoglobulin
as well reduced the number of relapses [62,90]. More-
over, in contrast to IFN-β or GA, breastfeeding is pos-
sible while receiving IVIG. If treatment with IVIG
already started during pregnancy, an even additional
reduction of relapse rate may be achieved [87]. Finally,
further large scale studies, preferably placebo controlled,
are required to confirm the positive effects of glucocorti-
coids and IVIG in the prevention of postpartum
relapses.
Being parent with MS
Many expectant mothers with MS ask themselves if they
will be able to deal with everyday life after delivery and
if despite their disease they will be able to be a good
mother. An important role in the daily routine of newly
minted mothers with MS plays the economizing of their
physical resources. As exhaustion affects even healthyTable 3 FDA pregnancy categories
FDA pregnancy category Description
B Animal studies have revealed no evidence of ha
adequate and well-controlled studies in pregnan
Or
Animal studies have shown an adverse effect, bu
in pregnant women have failed to demonstrate
C Animal studies have shown an adverse effect an
well-controlled studies in pregnant women.
Or
No animal studies have been conducted, and th
studies in pregnant women.
D Adequate well-controlled or observational studie
demonstrated a risk to the fetus. However, the b
potential risk. For example, the drug may be acc
situation or serious disease for which safer drug
X Adequate well-controlled or observational studie
demonstrated positive evidence of fetal abnorm
contraindicated in women who are or may becomothers during the first months after delivery, it impacts
mothers with MS in a particular degree. Interviews with
mothers with MS show that they pass on to a forward-
looking planning of daily household activities which
markedly alleviates to conserve their energies [17].
Female patients with children seem to have a higher
quality of life compared to childless MS patients, at least
concerning the domain of social function [91]. On the
other hand, in mothers with MS, the concern for chil-
dren correlates with depressive symptoms, but social
support may at least partly alleviate them [92]. Finally,
being a good mother and taking care for a baby is also
possible with a disease like MS, although the social sup-
port is even more important than for healthy mothers.
Conclusions
A lot of questions arise if patients with MS get pregnant
or plan to conceive. It is important not to discourage
these women but to comprehensively inform about pos-
sible risks and specific features of pregnancy in MS.
These include a slightly elevated risk for heredity, the
possibility of disease-related sexual dysfunctions and an
increase of relapse rate during puerperium. On the other
hand, specific complications during pregnancy or con-
genital abnormality are not to be feared for. Patients
have to be aware of limited knowledge about the effect
of various MS medication on pregnancy as well as that,
until now, an unambiguous recommendation of breast-
feeding is not possible. Thus, a weighting between risk
and benefit is frequently necessary, which should always
be done after detailed counseling and together with an
experienced physician. Prevention of postpartum relapses
poses a challenge for the future to encourage even more
patients to fulfill their desire to start a family.Drug
rm to the fetus; however, there are no
t women.
Glatiramer acetate
t adequate and well-controlled studies
a risk to the fetus in any trimester.
d there are no adequate and IFN-β, natalizumab,
fingolimod, dexamethasone,
prednisolone,
IVIG and cyclosporin Aere are no adequate and well-controlled
s in pregnant women have
enefits of therapy may outweigh the
eptable if needed in a life-threatening
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